With the approval and increasing use of [177Lu]Lu-PSMA-617 RLT, it has become apparent that low or heterogeneous PSMA expression may compromise the efficacy of RLT and be associated with short overall survival [26, 27], for example due to insufficient target dose to tumour lesions with low PSMA expression. The gene discussed is FOLH1; the disease is neoplasm.